<?xml version="1.0" encoding="UTF-8"?>
<p id="Par6">Electro-competent 
 <italic>Eschericia coli</italic> BL21(DE3)-pRIL cells were produced according to standard protocols
 <sup>
  <xref ref-type="bibr" rid="CR34">34</xref>
 </sup>. The following reagents were purchased from Applichem: LB medium (powder), ampicillin (used at 100 μg/mL) and chloramphenicol (used at 17 μg/mL), MnCl
 <sub>2</sub>, ammonium acetate, NaCl, MgCl
 <sub>2</sub>, ZnCl
 <sub>2</sub>, glycerol, imidazole, isopropyl-β-D-1-thiogalactopyranoside (IPTG), 1,4-dithiothreitol (DTT), phenylmethanesulfonyl fluoride (PMSF) and Tris base. 
 <italic>Dpn</italic>I restriction enzyme, BSA, Phusion
 <sup>®</sup> High-Fidelity (HF) DNA polymerase and Gibson Assembly
 <sup>®</sup> Master Mix were obtained from New England Biolabs. Stock solutions of ATP and GTP, SYTO
 <sup>TM</sup> 9 green fluorescent dye and HisPur
 <sup>TM</sup> Ni-NTA resin were purchased from ThermoFisher Scientific. pET28a and pET16b expression vectors were obtained from Novagen. Nucleotide analogs ribavirin 5′-triphosphate and cordycepin 5′-triphosphate were obtained from Jena Bioscience and Sigma-Aldrich, respectively. SYBR
 <sup>®</sup> Green II fluorescent dye, Tween 20, heparin, EDTA and oligonucleotides were also purchased from Sigma-Aldrich. ssRNA polyuridylic acid (poly-U), ssRNA polyadenylic acid (poly-A) and ssRNA polycytidylic acid (poly-C) were purchased from Amersham Biosciences. Radiolabeled nucleotides [α-
 <sup>32</sup>P]ATP and [α-
 <sup>32</sup>P]GTP (250 μCi; 3000 Ci/mmol) were obtained from Perkin Elmer. FMDV viral protein genome-linked 1 (VPg1) was synthetically prepared as previously described
 <sup>
  <xref ref-type="bibr" rid="CR35">35</xref>
 </sup>.
</p>
